42 related articles for article (PubMed ID: 11903386)
1. Self-reported symptom occurrence and distress, and psychological well-being after liver transplantation - a descriptive cross-sectional study of Danish recipients.
Dengsø KE; Knudsen AD; Møller DL; Forsberg A; Nielsen SD; Hillingsø J
Front Psychol; 2024; 15():1354706. PubMed ID: 38544518
[TBL] [Abstract][Full Text] [Related]
2. The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable?
James A; Mannon RB
Curr Transplant Rep; 2015 Jun; 2(2):113-121. PubMed ID: 26236578
[TBL] [Abstract][Full Text] [Related]
3. Red-Light-Activatable AND-Gated Antitumor Immunosuppressant.
Zhou Z; Zhang Y; Xia S; Chen X
Cells; 2023 Sep; 12(19):. PubMed ID: 37830565
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of salmon cartilage proteoglycan extends the survival of allografts in mice.
Asano K; Takahashi E; Yoshimura S; Nakane A
Biomed Rep; 2018 Jan; 8(1):37-40. PubMed ID: 29387389
[TBL] [Abstract][Full Text] [Related]
5. Symptom experienced three years after liver transplantation under immunosuppression in adults.
Wang C; Wang G; Yi H; Tan J; Xu C; Fang X; Yang Y; Li H; Chen Q; Chen G
PLoS One; 2013; 8(11):e80584. PubMed ID: 24260427
[TBL] [Abstract][Full Text] [Related]
6. The organ transplant symptom and well-being instrument - psychometric evaluation.
Forsberg A; Persson LO; Nilsson M; Lennerling A
Open Nurs J; 2012; 6():30-40. PubMed ID: 22523527
[TBL] [Abstract][Full Text] [Related]
7. Issues of adherence to immunosuppressant therapy after solid-organ transplantation.
Chisholm MA
Drugs; 2002; 62(4):567-75. PubMed ID: 11893226
[TBL] [Abstract][Full Text] [Related]
8. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
9. The first report from the patient outcomes registry for transplant effects on life (PORTEL): differences in side-effects and quality of life by organ type, time since transplant and immunosuppressive regimens.
Hathaway D; Winsett R; Prendergast M; Subaiya I
Clin Transplant; 2003 Jun; 17(3):183-94. PubMed ID: 12780666
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of an immunosuppressant side effect instrument.
Winsett RP; Arheart K; Stratta RJ; Alloway R; Wicks MN; Gaber AO; Hathaway DK
Prog Transplant; 2004 Sep; 14(3):210-6, 240. PubMed ID: 15495780
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppression, Race, and Donor-Related Risk Factors Affect De novo Cancer Incidence Across Solid Organ Transplant Recipients.
Bhat M; Mara K; Dierkhising R; Watt KDS
Mayo Clin Proc; 2018 Sep; 93(9):1236-1246. PubMed ID: 30064826
[TBL] [Abstract][Full Text] [Related]
12. Rurality and other factors associated with adherence to immunosuppressant medications in community-dwelling solid-organ transplant recipients.
Sankaranarayanan J; Collier D; Furasek A; Reardon T; Smith LM; McCartan M; Langnas AN
Res Social Adm Pharm; 2012; 8(3):228-39. PubMed ID: 21856247
[TBL] [Abstract][Full Text] [Related]
13. Report from the National Transplantation Pregnancy Registry: outcomes of pregnancy after transplantation.
Armenti VT; Daller JA; Constantinescu S; Silva P; Radomski JS; Moritz MJ; Gaughan WJ; McGrory CH; Coscia LA
Clin Transpl; 2006; ():57-70. PubMed ID: 18368705
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressant side effect profile does not differ between organ transplant types.
Winsett RP; Stratta RJ; Alloway R; Wicks MN; Hathaway DK
Clin Transplant; 2001; 15 Suppl 6():46-50. PubMed ID: 11903386
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
